Literature DB >> 16282154

Sympathetic ophthalmia.

Francisco Max Damico1, Szilárd Kiss, Lucy H Young.   

Abstract

Sympathetic ophthalmia is a rare, bilateral granulomatous uveitis that occurs after either surgical or accidental trauma to one eye. The ocular inflammation in the fellow eye becomes apparent usually within 3 months after injury. Clinical presentation is an insidious or acute anterior uveitis with mutton-fat keratic precipitates. The posterior segment manifests moderate to severe vitritis, usually accompanied by multiple yellowish-white choroidal lesions. Evidence suggests that sympathetic ophthalmia represents an autoimmune inflammatory response against choroidal melanocytes mediated by T cells. Diagnosis is based on clinical findings and a history of previous ocular trauma or surgery. Other causes of granulomatous uveitis, such as Vogt-Koyanagi-Harada disease, sarcoidosis, tuberculosis, and syphilis should be considered. Treatment of sympathetic ophthalmia consists of systemic anti-inflammatory agents with high dose oral corticosteroid as the drug of choice. However, if the inflammation cannot be controlled, cyclosporine is then used. Other immunosuppressive agents, such as chlorambucil, cyclophosphamide or azathioprine, may be necessary for the control of inflammation. The role of enucleation after the diagnosis of sympathetic ophthalmia remains controversial. Visual prognosis is reasonably good with prompt wound repair and appropriate immunomodulatory therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282154     DOI: 10.1080/08820530500232100

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  24 in total

1.  [Sympathetic ophthalmia : Therapy with steroid-free immunosuppressant azathioprine].

Authors:  K Wand; M Straub; C P Lohmann; C S Mayer
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

Review 2.  How dying cells alert the immune system to danger.

Authors:  Hajime Kono; Kenneth L Rock
Journal:  Nat Rev Immunol       Date:  2008-03-14       Impact factor: 53.106

3.  Retinal laser burn disrupts immune privilege in the eye.

Authors:  Hong Qiao; Kenyatta Lucas; Joan Stein-Streilein
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 4.  Gender disparities in ocular inflammatory disorders.

Authors:  Hatice Nida Sen; Janet Davis; Didar Ucar; Austin Fox; Chi Chao Chan; Debra A Goldstein
Journal:  Curr Eye Res       Date:  2014-07-02       Impact factor: 2.424

Review 5.  Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.

Authors:  Marcella Prete; Rosanna Dammacco; Maria Celeste Fatone; Vito Racanelli
Journal:  Clin Exp Med       Date:  2015-03-28       Impact factor: 3.984

6.  A 36-year-old man with a red eye.

Authors:  Drew Chronister; Evan Waxman
Journal:  Digit J Ophthalmol       Date:  2008-04-13

7.  Reversible retinal changes in the acute stage of sympathetic ophthalmia seen on spectral domain optical coherence tomography.

Authors:  Vishali Gupta; Amod Gupta; M R Dogra; Inderpreet Singh
Journal:  Int Ophthalmol       Date:  2011-02-18       Impact factor: 2.031

8.  Sympathetic ophthalmia: what have we learned?

Authors:  H Nida Sen; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2009-11       Impact factor: 5.258

Review 9.  Sympathetic ophthalmia.

Authors:  Claudia Patricia Castiblanco; Ron A Adelman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-16       Impact factor: 3.117

10.  Sympathetic ophthalmia following vitreoretinal surgery.

Authors:  Zeynep Ozbek; Gul Arikan; Aylin Yaman; Hakan Oner; Meltem Soylev Bajin; A Osman Saatci
Journal:  Int Ophthalmol       Date:  2009-07-09       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.